Trial · NCT02880241

MMV390048 POC in Patients With P. Vivax and P. Falciparum Malaria

NCT02880241, Phase 2, Terminated, Medicines for Malaria Venture; results first posted 2021-12-09

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. MMV390048 POC in Patients With P. Vivax and P. Falciparum Malaria. Trials, record NCT02880241. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02880241

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: MMV390048 POC in Patients With P. Vivax and P. Falciparum Malaria
NCT number: NCT02880241
Status: Terminated
Phases: Phase 2
Enrollment: 8 participants, actual
Lead sponsor: Medicines for Malaria Venture
Conditions: Malaria
Interventions: MMV390048
First posted: 2016-08-26
Last updated: 2021-12-09
Results first posted: 2021-12-09

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants With Crude Adequate Clinical and Parasitological Response (ACPR) for P. Vivax	On Day 14 post-dose	The absence of parasitaemia (thick smear) on Day 14, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure, late clinical failure or late parasitological failure. Parasitaemia was defined as a P. vivax asexual forms count \>0
Primary	For P. Falciparum: PCR-adjusted Crude Adequate Clinical and Parasitological Response (ACPR)	On Day 14 post-dose	Number of participants meeting PCR-adjusted Crude Adequate Clinical and Parasitological Response (ACPR)

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants With Crude Adequate Clinical and Parasitological Response (ACPR) for P. Vivax	On Day 14 post-dose	All enrolled participants who received any amount of study medication.	participants	NUMBER
PRIMARY	For P. Falciparum: PCR-adjusted Crude Adequate Clinical and Parasitological Response (ACPR)	On Day 14 post-dose	Cohort 1B - P falciparum malaria did not enroll participants.

Source ClinicalTrials.gov

Results by group1

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Number of Participants With Crude Adequate Clinical and Parasitological Response (ACPR) for P. Vivax	Cohort 1A - P. Vivax Malaria		8		participants

Source ClinicalTrials.gov

Participant flow18

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Cohort 1A - P. Vivax Malaria	8
Overall Study	STARTED	Cohort 1B - P. Falciparum Malaria	0
Overall Study	STARTED	Cohort 2A - P. Vivax Malaria	0
Overall Study	STARTED	Cohort 2B - P. Falciparum Malaria	0
Overall Study	STARTED	Cohort 3A - P. Vivax Malaria	0
Overall Study	STARTED	Cohort 3B - P. Falciparum Malaria	0
Overall Study	COMPLETED	Cohort 1A - P. Vivax Malaria	7
Overall Study	COMPLETED	Cohort 1B - P. Falciparum Malaria	0
Overall Study	COMPLETED	Cohort 2A - P. Vivax Malaria	0
Overall Study	COMPLETED	Cohort 2B - P. Falciparum Malaria	0

1 to 10 of 18Source ClinicalTrials.gov

See all 18 participant flow

Adverse events120

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Abdominal discomfort	Gastrointestinal disorders	Cohort 1B - P. Falciparum Malaria	0	0
other	Abdominal discomfort	Gastrointestinal disorders	Cohort 1A - P. Vivax Malaria	2	8
other	Abdominal discomfort	Gastrointestinal disorders	Cohort 2A - P. Vivax Malaria	0	0
other	Abdominal discomfort	Gastrointestinal disorders	Cohort 2B - P. Falciparum Malaria	0	0
other	Abdominal discomfort	Gastrointestinal disorders	Cohort 3A - P. Vivax Malaria	0	0
other	Abdominal discomfort	Gastrointestinal disorders	Cohort 3B - P. Falciparum Malaria	0	0
other	Abdominal pain	Gastrointestinal disorders	Cohort 1B - P. Falciparum Malaria	0	0
other	Abdominal pain	Gastrointestinal disorders	Cohort 1A - P. Vivax Malaria	1	8
other	Abdominal pain	Gastrointestinal disorders	Cohort 2A - P. Vivax Malaria	0	0
other	Abdominal pain	Gastrointestinal disorders	Cohort 2B - P. Falciparum Malaria	0	0

1 to 10 of 120Source ClinicalTrials.gov

See all 120 adverse events

Adverse event totals18

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Cohort 1B - P. Falciparum Malaria	0	0
Total, all-cause mortality	Cohort 1A - P. Vivax Malaria	0	8
Total, all-cause mortality	Cohort 2A - P. Vivax Malaria	0	0
Total, all-cause mortality	Cohort 2B - P. Falciparum Malaria	0	0
Total, all-cause mortality	Cohort 3A - P. Vivax Malaria	0	0
Total, all-cause mortality	Cohort 3B - P. Falciparum Malaria	0	0
Total, other adverse events	Cohort 1B - P. Falciparum Malaria	0	0
Total, other adverse events	Cohort 1A - P. Vivax Malaria	8	8
Total, other adverse events	Cohort 2A - P. Vivax Malaria	0	0
Total, other adverse events	Cohort 2B - P. Falciparum Malaria	0	0

1 to 10 of 18Source ClinicalTrials.gov

See all 18 adverse event totals

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
36509063	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02880241

GET https://conductscience.org/api/trials/v1/NCT02880241/events?page=2

API reference For AI assistants